French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Friday the appointment of Mariette Finet as a director to its board of directors, effective immediately.

Finet succeeds Michele Ollier, who resigned from her position as director on 1 August 2026.

A Doctor of Medicine, Finet brings more than 35 years of experience across the healthcare, pharmaceutical and life sciences sectors. Finet began her career in the Medical Department of Laboratoires Beaufour in Paris, where she held positions in pharmaceutical asset analysis and conducted clinical research across several therapeutic areas, with a particular focus on gastroenterology. She subsequently joined Beaufour-Ipsen Pharma and later Ipsen, where she held positions in the Marketing Department.

Since 2007, Finet has served in scientific and medical advisory roles at Mayroy and Highrock S.ar.l., providing expertise in investment analysis and portfolio oversight, with a particular focus on pharmaceutical, MedTech and life sciences sectors. She also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd.

Finet will also join the Ipsen board's Portfolio Committee, succeeding Ollier.

Following this appointment, Ipsen's board of directors continues to comprise 14 directors, with balanced representation of seven women and seven men.